The Cardiotoxic Effects of Remdesivir Administered to the Patients with SARS-CoV Infection

Posted on : By
The Cardiotoxic Effects of Remdesivir Administered to the Patients with SARS-CoV Infection
J Young Pharm. Vol 15/Issue 4/2023 
Dharti Bhagat1, Sefali Patel1, Manoj Dikkatwar2 and Radhika Bindu1
Author informationArticle notesCopyright and License informationCitations

1Department of Pharmacy Practice, Parul University, Vadodara, Gujarat, INDIA

2Department of Pharmacy Practice, DY Patil University School of Pharmacy, Affiliated to DY Patil (Deemed to be University), Nerul, Navi Mumbai, Maharashtra, INDIA

Corresponding author.

Correspondence: Dr. Radhika Bindu Department of Pharmacy Practice, Assistant Professor, Parul Institute of Pharmacy, Parul University, Gujarat, INDIA. Email: radhikasaddu94@gmail.com
Received June 19, 2023; Revised July 24, 2023; Accepted August 13, 2023.
Copyright 2023 Authors
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Citation

1.Bhagat D, Patel S, Dikkatwar M, Bindu R. The Cardiotoxic Effects of Remdesivir Administered to the Patients with SARS-CoV Infection. Journal of Young Pharmacists [Internet]. 2023 Dec 22;15(4):767–9. Available from: http://dx.doi.org/10.5530/jyp.2023.15.107
Copy to clipboard
Published in: Journal of Young Pharmacists, 2023 15(4): 767-769. Published online: 07 December 2023DOI: 10.5530/jyp.2023.15.107

ABSTRACT

Coronavirus has become a pandemic without a reliable treatment since December 2019. The antiviral medication remdesivir, which also inhibits one of the most powerful viral RNA enzymes, RNA dependent RNA polymerase, prevents the SARS-CoV virus from reproducing. Cardiomyocytes can experience substantial cytotoxic effects from remdesivir. Remdesivir binds to human mitochondrial RNA polymerase, which causes cardiotoxicity. A prolonged QT interval and the emergence of torsade de pointes could result from lengthening the field potential duration while lowering the amplitude of the Na+ peak and the pace of spontaneous beating in a dose-dependent way. The current safety profile of Remdesivir is not yet completely established, and it is necessary to evaluate the safety profile and any potential adverse cardiovascular consequences by conducting additional clinical trials. In this case report, adverse effects of remdesivir to assess its safety profile in Covid-19 patients is reviewed.

Keywords: SARS-CoV, Remdesivir, Adverse effect, QT prolongation, Cardiotoxicity, Bradycardia